Andrew Brooks, 51, died on Jan. 23, the university said, adding that he “led the creation of the first coronavirus saliva-based test, which received FDA emergency approval last spring and has played a significant role in the fight against the COVID-19 pandemic,” said Rutgers, which is located in New Jersey.
“More than four million rapid response tests, which were the first approved for home use, have been performed since March, earning Brooks and his lab’s pioneering work recognition” by legacy media outlets, said the college.
Last week, New Jersey Gov. Phil Murphy honored Brooks and called him “one of our state’s unsung heroes.”
Jay Tischfield, the head of Rutgers’ RUCDR division, said in a statement that Brooks “will be fondly remembered by the large cohort of scientists whose research he facilitated across many years.”
Last year, Brooks made reference to the saliva test, which serves as an alternative to the nasal PCR tests.
Rutgers did not elaborate on his cause of death.